Patient-tailored modulation of the immune system may revolutionize future lung cancer treatment
ME Heuvers, JG Aerts, R Cornelissen, H Groen… - BMC cancer, 2012 - Springer
Cancer research has devoted most of its energy over the past decades on unraveling the
control mechanisms within tumor cells that govern its behavior. From this we know that the …
control mechanisms within tumor cells that govern its behavior. From this we know that the …
Decreased levels of serum cytokeratin 19 fragment CYFRA 21‑1 predict objective response to chemotherapy in patients with non-small cell lung cancer
LI Pang, J Wang, Y Jiang… - Experimental and …, 2013 - spandidos-publications.com
Diagnostic tools capable of predicting early responses to chemotherapy are required to
improve the individual management of cancer patients. The present study aimed to evaluate …
improve the individual management of cancer patients. The present study aimed to evaluate …
[HTML][HTML] Increased plasma miRNA-30a as a biomarker for non-small cell lung cancer
L Sun, Y Chen, Q Su, X Tang, Y Liang… - … Medical Journal of …, 2016 - ncbi.nlm.nih.gov
Increased Plasma miRNA-30a as a Biomarker for Non-Small Cell Lung Cancer - PMC Back to
Top Skip to main content NIH NLM Logo Access keys NCBI Homepage MyNCBI Homepage …
Top Skip to main content NIH NLM Logo Access keys NCBI Homepage MyNCBI Homepage …
[HTML][HTML] Value of serum marker HE4 in pulmonary carcinoma diagnosis
QF Tang, ZW Zhou, HB Ji, WH Pan… - International Journal of …, 2015 - ncbi.nlm.nih.gov
An effective blood test is valuable to aid clinicians in making case management decisions.
The present study was to analyze the value of four serum tumor markers for the diagnosis of …
The present study was to analyze the value of four serum tumor markers for the diagnosis of …
Comparison of serum MicroRNA21 and tumor markers in diagnosis of early non‐small cell lung cancer
M Sun, J Song, Z Zhou, R Zhu, H Jin, Y Ji… - Disease …, 2016 - Wiley Online Library
Objective. To compare the clinical value of serum microRNA21 (miR21) and other tumor
markers in early diagnosis of non‐small cell lung cancer (NSCLC). Methods. Serums …
markers in early diagnosis of non‐small cell lung cancer (NSCLC). Methods. Serums …
Discovery of lung squamous carcinoma biomarkers by profiling the plasma peptide with LC/MS/MS
Y Liu, XH Xun, JM Yi, Y Xiang, J Hua - Chinese Chemical Letters, 2017 - Elsevier
Biomarkers can be used for the screening and clinical diagnosis of cancer, and peptidomics
approach has been proven successful in the research of biomarkers. To develop better …
approach has been proven successful in the research of biomarkers. To develop better …
Effect of gefitinib on serum EGFR and CYFRA21‑1 in patients with advanced non‑small cell lung cancer
H Ren, Y Hu, T Xie, C Jin, Y Hu… - Oncology …, 2019 - spandidos-publications.com
Abstract Changes of epidermal growth factor receptor (EGFR) and cytokeratin fragment
antigen 21‑1 (CYFRA21‑1) in patients with advanced non‑small cell lung cancer (NSCLC) …
antigen 21‑1 (CYFRA21‑1) in patients with advanced non‑small cell lung cancer (NSCLC) …
CYFRA 21-1 is an early predictor of chemotherapeutic effectiveness in advanced nonsmall cell lung cancer: an observational study
T Zhao, Y Jin, G Mao, Y Wei, G Wu, X Ye, Y Zhou… - Medicine, 2016 - journals.lww.com
Abstract Serum cytokeratin 19 fragment (CYFRA21-1) has been found to be a useful
prognostic marker in lung cancer. Previous studies have revealed that change in CYFRA21 …
prognostic marker in lung cancer. Previous studies have revealed that change in CYFRA21 …